Haploidentical hematopoietic stem cell transplantation compared to immunosuppressive therapy plus eltrombopag as first-line treatment for severe aplastic anemia patients aged 40-65: a multicenter retrospective study. (PubMed, Ann Hematol) - Oct 21, 2026 - "Meanwhile, the 3-year failure-free survival (FFS) was significantly higher in the HID-HSCT group among patients aged 40-49 (82.9% vs. 60.1%, P = 0.045), whereas no difference was observed in those aged 50-65 (P = 0.984). HID-HSCT may offer more durable benefits in selected SAA patients aged 40-49, while its advantage over IST+EPAG is not evident in patients aged 50-65."
Clinical • Journal • Retrospective data • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Hematological Disorders • Transplantation
|
|
Cong Xu; Dongjun Lin; Guiping Chen; Liangliang Wu; Ming Zhou; Ruiqing Zhou; Shilin Xu; Shunqing Wang; Wenjian Mo; Xiaohui Xiao; Xiaowei Chen; Xiaoyan Liu; Yumiao Li; Yuping Zhang
|